» Articles » PMID: 21087983

CD34, CD117, and Ki-67 Expression in Phyllodes Tumor of the Breast: an Immunohistochemical Study of 33 Cases

Overview
Publisher Sage Publications
Date 2010 Nov 20
PMID 21087983
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Phyllodes tumors (PTs) of the breast are biphasic lesions, comprising an epithelial component set within a neoplastic spindle-celled stroma. These tumors have been classified as benign, borderline, and malignant based on a combination of histological criteria, including stromal cellularity, nuclear pleomorphism, mitotic rate, stromal overgrowth, and margin appearance. The aim of this study was to evaluate the expression of CD34, CD117 (c-kit), and Ki-67 in PT of the breast and attempt to correlate the staining pattern with tumor grade by morphology. Immunohistochemical expression of CD117, CD34, and Ki-67 was studied on formalin-fixed, paraffin-embedded archival tissue material from 33 cases of PT. Histologically, there were 21 benign, 6 borderline, and 6 malignant (high-grade) tumors. All 6 histologically malignant PTs were positive for CD117 (100%), but only 1 marked with CD34 (16.7%). Borderline PTs frequently coexpressed CD34 and CD117 (66.7%). The benign PTs, on the other hand, most commonly (52.4%) showed a CD34(+)/CD117(-) immunoprofile with 33.3% cases coexpressing the markers: that is, CD34(+)/CD117(+). Although most benign PTs (80.6%) showed a Ki-67 of <2%, a few cases showed slightly higher proliferation indices. This study indicates that CD34 and CD117 are differentially expressed in benign and malignant PTs. These markers, therefore, in combination, may be used as an adjunct to morphology in the subclassification of PTs.

Citing Articles

Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study.

Lei T, Song Y, Shen Z, Shi Y, Xia C, Deng X Transl Oncol. 2025; 53:102318.

PMID: 39922047 PMC: 11849116. DOI: 10.1016/j.tranon.2025.102318.


Co expression of EGFR and CD10 in patients with phyllodes tumors of the breast: a single center experience in North Western Algeria.

Belhadj A, Brikci S, Akhrouf C, Belhadj A, Medjamia M, Sahraoui T Afr Health Sci. 2024; 23(4):266-274.

PMID: 38974258 PMC: 11225475. DOI: 10.4314/ahs.v23i4.29.


Clinical perspectives and outcomes of the giant breast phyllodes tumor and sarcoma: a real-world retrospective study.

Liu N, Kang Y, Qu N, Kong C, Han Y BMC Cancer. 2023; 23(1):801.

PMID: 37635229 PMC: 10463853. DOI: 10.1186/s12885-023-11279-2.


Prognostic factors of breast phyllodes tumors.

Shin E, Koo J Histol Histopathol. 2023; 38(8):865-878.

PMID: 36866915 DOI: 10.14670/HH-18-600.


Diagnostic difficulties in giant benign phyllodes tumor.

Matei R, Mehedintu-Ionescu M, Paitici S, Georgescu E, Donoiu A, Ghemigian A Rom J Morphol Embryol. 2022; 62(4):1035-1044.

PMID: 35673823 PMC: 9289689. DOI: 10.47162/RJME.62.4.16.